The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,748.50
Bid: 1,748.00
Ask: 1,748.50
Change: 15.00 (0.87%)
Spread: 0.50 (0.029%)
Open: 1,736.00
High: 1,750.00
Low: 1,736.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK WINNERS & LOSERS SUMMARY: Moneysupermarket Shines After Strong 2019

Thu, 20th Feb 2020 10:50

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Thursday.

----------

FTSE 100 - WINNERS

----------

Smith & Nephew, up 8.5%. The medical devices maker reported mid-single-digit revenue growth in 2019, but profit slipped due to an increase in costs. The company reported pretax profit of USD743 million in 2019, down 4.9% from USD781 million in 2018, amid higher selling, general & administrative expenses, which rose to USD2.69 billion from USD2.50 billion. Revenue, meanwhile, grew by 4.8% to USD5.14 billion from USD4.90 billion year-on-year. Smith & Nephew declared a 23.1 US cents a share final dividend, taking the total distribution to 37.5 US cents, up 4% year-on-year. Looking forward, Smith & Nephew said it expects its underlying revenue growth to be in the range of 3.5% to 4.5% in 2020. In addition, the company said it expects to deliver a 2020 trading profit margin at or slightly above 2019 level of 22.8%. In 2018, trading margin stood at 22.9%.

----------

Lloyds Banking Group, up 3.5%. The lender reported a sharp fall in profit for 2019, which was blamed on a significant rise in payment protection insurance provisions, but said it was pleased with its underlying performance. In 2019, Lloyds recorded pretax profit of GBP4.39 billion, which was down 26% on 2018's GBP5.96 billion and 1.8% below the GBP4.47 billion consensus of market forecasts compiled by the company. On an underlying basis, net interest income was GBP12.38 billion, which was in line with market consensus, but 2.6% lower year-on-year from GBP12.71 billion. Net income totalled GBP17.14 billion, again in line with consensus, but down 3.5% from GBP17.77 billion in 2018. The bank upped its total dividend for 2019 to 3.37 pence, 5.0% higher than the 3.21p distributed in 2018. "Concerns about the balance sheet, which had been mounting in recent weeks, appear to have been allayed for now and the bank has committed to capital generation targets which should underpin the dividend and may even allow the resumption of share buybacks suspended last year," said AJ Bell's Russ Mould.

----------

BAE Systems, up 3.5%. The defence company reported a rise in sales and revenue and said 2019 had been "a year of significant progress for the company". The Farnborough-based company said revenue was GBP18.3 billion, up 8.9% from GBP16.8 million in 2018. Bloomberg consensus, provided by BAE, expected GBP19.8 billion in revenue. The company said good results were underpinned by improving operational performance as governments in key markets continue to prioritise defence and security. Pretax profit was 33% higher at GBP1.6 billion compared to GBP1.2 billion in 2018, while underlying earnings before interest, tax, depreciation and amortization was GBP2.2 billion compared to GBP1.9 billion a year ago. BAE proposed a final dividend of 13.8 pence. making a total of 23.2p per share for the year, an increase from 22.2 pence in 2018. Looking ahead, the company said it expects 2020 underlying earnings per share to "grow by mid-single digit percentage".

----------

Anglo American, up 1.7%. The miner reported an improvement in earnings in 2019 and raised its dividend. Anglo American posted an 8% revenue rise to USD29.87 billion from USD27.61 billion last year. Profit attributable to shareholders for 2019 came in at USD3.54 billion, broadly unchanged from 2018. Underlying earnings before interest, tax, depreciation and amortisation were up 9.2% to USD10.01 billion in 2019 from USD9.16 the year before. Underlying Ebitda at its Platinum Group Metals unit doubled to USD2 billion from USD1 billion. Anglo American upped its dividend by 9.0% to 1.09 cents from 1.00 cents per share. "The benefits of a soaring palladium price are laid out in Anglo American's results where its platinum group metals earnings have nearly doubled in the past year. Strong iron ore prices have also contributed to an overall boost in group earnings," said Aj Bell's Mould.

----------

FTSE 100 - LOSERS

----------

Imperial Brands, down 6.0%, GlaxoSmithKline, down 1.5%. The stocks went ex-dividend meaning new buyers no longer qualify for the latest payout.

----------

AVEVA Group, down 2.8%. The engineering and industrial software company said revenue has grown in its financial year to date, but warned that coronavirus is hurting its operations in China. The company said it has achieved high single-digit organic constant currency revenue growth in the ten months to the end of January. AVEVA explained that growth was supported by "strong orders" in Rental & Subscription, partly offset by "significantly" lower Initial & Perpetual licences. On a regional basis, the Cambridge-headquartered company said it has achieved growth across all of its reporting segments, with particularly "good" growth in Asia Pacific. AVEVA said the ongoing disruption in China - caused by the coronavirus - is hurting its sales in that country due to travel restrictions and office closures. China has historically accounted for around 5% of AVEVA's overall revenue.

----------

FTSE 250 - WINNERS

----------

Moneysupermarket.com, up 13%. The price comparison website reported profit growth and boosted its dividend in what was a "standout" year for it MoneySavingExpert energy UK price site. In 2019, revenue was 9.2% higher at GBP388.4 million from GBP355.6 million, with pretax profit rising 8.5% to GBP116.0 million from GBP106.9 million. Moneysupermarket edged its full-year payout 6.0% higher to 11.71 pence per share from 11.05p. Estimated customer savings, one of the company performance indicators, dipped 4.8% to GBP2.0 billion from GBP2.1 billion in 2018. Another key performance tracker is active users, which rose 1.6% to 13.1 million from 12.9 million. The company said the MoneySavingExpert website attracted "record visitors" in 2019.

----------

TBC Bank, up 5.0%. The lender reported a double-digit rise in annual profit as the bank's loan book saw strong growth from a sharp rise in Corporate lending. For 2019, the Georgian bank recorded GEL585.5 million in pretax profit, about GBP160.6 million, which is 15% higher compared to GEL510.2 million in 2018. TBC's net interest income rose 3.0% in 2019 to GEL801.5 million from GEL778.0 million the year before. The lender's operating expenses rose 9.7% in 2019 to GEL450.7 million from GEL411.0 million in 2018, and, as a result, its cost-to-income ratio worsened to 39.9% from 37.8%.

----------

FTSE 250 - LOSERS

----------

Micro Focus International, down 2.0%. UBS downgraded the Newbury-based software firm to Neutral from Buy.

----------

OTHER MAIN MARKET AND AIM - LOSERS

----------

Norcros, down 20%. The UK and South African kitchen and bathroom products firm said it expects underlying profitability for its financial year to March 31 to be below market expectations, as the coronavirus affects its China-based suppliers. Norcros said the coronavirus has had little short-term impact to date, as UK based stock levels have been sufficient to satisfy demand. But slower production at its China-based suppliers is "likely to have some impact on the seasonally important remainder of this financial year and early next year". "The situation however remains fluid and is being closely monitored and actively managed," the company noted. Norcros said it has continued to win market share in its major markets despite conditions remaining challenging since mid-November. The company now expects that underlying profitability for the financial year to March 31 will be below market expectations, albeit ahead of last year. In financial 2019, Norcros reported revenue of GBP331.0 million. Revenue from the UK was GBP228.1 million, while South Africa revenue was GBP102.9.

----------

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
18 Dec 2023 07:18

GSK sees success in Jemperli endometrial cancer trial

(Sharecast News) - GSK released positive headline results from the planned analysis of its trial of Jemperli in endometrial cancer on Monday.

Read more
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.